Emerging targeted therapies in triple-negative breast cancer

Annals of Oncology

Volumn 23, Issue SUPPL. 6, 2012, Pages

  Crown, J ^a,b   O'Shaughnessy, J ^c   Gullo, G ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Targeted; Therapies; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; APATINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; EPIRUBICIN; ERIBULIN; GEMCITABINE; IXABEPILONE; NERATINIB; NIRAPARIB; OLAPARIB; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; RUCAPARIB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA REPAIR; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; VOMITING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; POLY ADENOSINE DIPHOSPHATE RIBOSE; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84867118148     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds196     Document Type: Article

References (79)

1. Brenton JD, Carey LA, Ahmed AA et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23: 7350-7360.
2. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010; 220: 263-280.
3. Bertucci F, Finetti P, Cervera N et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123: 236-240.
4. Rakha EA, Elsheikh SE, Aleskandarany MA et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-2310.
5. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010; 134: 907-922.
6. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
7. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
8. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010; 19: 312-321.
9. Bajorin D, Bosl GJ, Fein R. Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol 1987; 5: 1589-1593.
10. Booth BW, Weiss RB, Korzun AH et al. Phase II trial of carboplatin in advanced breast carcinoma: a Cancer and Leukemia Group B Study. Cancer Treat Rep 1985; 69: 919-920.
11. Carmo-Pereira J, Olivera-Costa F, Henriquez E. Carboplatin as primary chemotherapy for disseminated breast carcinoma: a phase II study. 5th European Conference on Clinical Oncology, September 3-7, 1989, London: Abstr P0971.
12. Forastiere AA, Hakes TB, Wittes JT et al. Cisplatin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol 1982; 5: 243-247.
13. Kolaric K, Roth A. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983; 11: 108-112.
14. Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer patients - results of a phase II study. Cancer Chemother Pharmacol 1991; 27: 409-412.
15. Martin M, Diaz-Rubio E, Casado A et al. Phase II study of carboplatin in advanced breast cancer: preliminary results. Semin Oncol 1991; 18: 23-27.
16. Mechl Z, Sopkova B. CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma 1984; 31: 431-435.
17. O'Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993; 11: 2112-2117.
18. Ostrow S, Egorin M, Aisner J et al. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 1980; 3: 23-27.
19. Sledge GW, Jr, Loehrer PJ, Sr, Roth BJ et al. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988; 6: 1811-1814.
20. Yap HY, Salem P, Hortobagyi GN et al. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep 1978; 62: 405-408.
21. Denduluri N, Swain S. Ixabepilone: clinical role in metastatic breast cancer. Clin Breast Cancer 2011; 11: 139-145.
22. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010; 121: 261-271.
23. Rugo HS, Roche H, Thomas E et al. Ixabepilone plus capecitabine versus capecitabine in patients with triple-negative tumours: a pooled analysis from two large phase III clinical studies. Proceedings of the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, TX; AACR Philadelphia, PA: Abstr 3057.
24. Rugo HS, Campone M, Amadori D et al. Randomised phase II study of weekly versus every-3-week ixabepilone plus bevacizumab versus paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 15s: Abstr 1029.
25. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 2011; 377: 914-923.
26. Twelves C, Akerele C, Wanders J et al. Eribulin mesylate (E7389) versus treatment of physician's choice (TPC) in patients (PTS) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Ann Oncol 2010; 21: 8s: Abstr 275O.
27. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005; 23: 1782-1790.
28. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
29. Thomssen C, Pierga J-Y, Pritchard KI et al. First-line bevacizumab (Bev) combination therapy in triple-negative (TN) locally recurrent/metastatic breast cancer (LR/MBC): subpopulation analysis of study MO19391 in >2000 patients (Pts). Proceedings of the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, TX; AACR Philadelphia, PA: Abstr 6093.
30. Robert NJ, Diéras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
31. Brufsky A, Valero V, Tiangco B et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2. J Clin Oncol 2010; 28: 15s: Abstr 1010.
32. Gerber B, Eidtmann H, Rezai M et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: secondary endpoint analysis of the Gepar-Quinto study (GBG 44). J Clin Oncol 2011; 29: 15s: Abstr 1006.
33. Bear HD, Tang G, Rastogi P et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011; 29: 15s: Abstr LBA1005.
34. Tyagi P, Lee D, Reddy GK. Highlights from the 4th International Congress on Colorectal Cancer; Aventura, Florida, October 2005. J Clin Colorectal Cancer 2005; 5: 236-241.
35. Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-1816.
36. Baselga J, Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H et al. SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Proceedings of the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, TX; AACR Philadelphia, PA: Abstr 45.
37. Barrios CH, Liu MC, Lee SC et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121-131.
38. Bianchi G, Loibl S, Zamagni C et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009; 20: 616-624.
39. Bergh J, Greil R, Voytko N et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010; 28: 18s: Abstract LBA1010.
40. Crown J, Dieras V, Staroslawska E et al. Phase III evaluation of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010; 28: 18s: Abstr LBA1011.
41. Ionta MT, Atzori F, Deidda MC et al. Prognostic role of ER+ associated with other clinical and biological features in patients with T4 breast cancer achieving less than a pathological complete response (
42. Spigel DR, Hainsworth JD, Burris HA, III et al. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. Clin Adv Hematol Oncol 2011; 9: 280-286.
43. Corkery B, Crown J, Clynes M et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009; 20: 862-867.
44. Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008; 26: 15s: Abstr 1009.
45. O'Shaughnessy J, Weckstein DJ, Vukelja SJ et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106: 308.
46. Baselga J, Gomez P, Awada A et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II study (BALI-1). Ann Oncol 2010; 21: 8s: Abstr 274O.
47. Carey LA, O'Shaughnessy J, Hoadley K et al. Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials. Proceedings of the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 9-13, 2009, San Antonio, TX; AACR Philadelphia, PA: Abstr 2014.
48. Baselga J, Albanell J, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23: 5323-5333.
49. Dickler MN, Rugo HS, Eberle CA et al. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 2008; 14: 7878-7883.
50. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
51. Gluz O, Liedtke C, Gottschalk N et al. Triple-negative breast cancer - current status and future directions. Ann Oncol 2009; 20: 1913-1927.
52. Gajria D, King TA, Pannu H et al. Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: a phase I study in patients with metastatic HER2-amplified breast cancer. J Clin Oncol 2011; 29: 15s: Abstr 574.
53. Dantzer F, de La Rubia G, Ménissier-De Murcia J et al. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 2000; 39: 7559-7569.
54. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-8115.
55. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007; 96: 11-15.
56. Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-2132.
57. Tommiska J, Bartkova J, Heinonen M et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008; 27: 2501-2516.
58. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010; 70: 7970-7980.
59. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
60. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
61. Khan OA, Gore M, Lorigan P et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011; 104: 750-755.
62. Isakoff SJ, Overmoyer B, Tung NM et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010; 28: 18s: Abstr 1019.
63. Ossovskaya V, Lingyun L, Broude E et al. BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer. Proc Am Assoc Cancer Res, April 18-22, 2009, Denver, CO; AACR Philadelphia, PA: Abstr 5552.
64. Ossovskaya V, Lim C, Schools G. Cell cycle effects of iniparib, a PARP inhibitor, in combination with gemcitabine and carboplatin in the MDA-MB-468(-) triplenegative breast cancer (TNBC) cell line. Proceedings of the 33rd Annual CTRCAACR San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX; AACR Philadelphia, PA: Abstr P5-06-09.
65. Ossovskaya V, Lim C, Schools G et al. The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468(-) triplenegative breast cancer (TNBC) cell line. Proc Am Assoc Cancer Res, April 2-6, 2011, Orlando, FL; AACR Philadelphia, PA: Abstr LB-401.
66. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
67. O'Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29: 15s: Abstr 1007.
68. Saal LH, Holm K, Maurer M et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2 are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554-2559.
69. Ellard SL, Clemons M, Gelmon KA et al. Randomised phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-4541.
70. Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ " triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326.
71. Tryfonopoulos D, Walsh S, Collins DM et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol 2011; 22: 2234-2240.
72. Fornier MN, Morris PG, Abbruzzi A et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 2011; 22: 2575-2581.
73. Finn RS, Bengala C, Ibrahim N et al. Phase II trial of dasatinib in triplenegative breast cancer: results of study CA180059. Proceedings of the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, TX; AACR Philadelphia, PA: Abstr 3118.
74. Whitesell L, Mimnaugh EG, De Costa B et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91: 8324-8328.
75. Caldas-Lopes E, Cerchietti L, Ahn JH et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009; 106: 8368-8373.
76. Marotta LL, Almendro V, Marusyk A et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735.
77. http://www.incyte.com/drugs_product_pipeline.html (6 January 2012, date last accessed).
78. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
79. http://clinicaltrials.gov (6 January 2012, date last accessed).